Ge Healthcare Bio-sciences Ab

Cytiva Bioprocess R&d Ab

Ge Healthcare Bioprocess R&d Ab

Ge Healthcare Bioprocess R&d

Sture Larsson

Gustav Jose Rodrigo

Martin Hall

Per-Mikael Aberg

Jinyu Zou

Andreas Muranyi

Per-Mikael ÅBerg

The present invention relates to a chromatography ligand, which comprises Domain C fromprotein A (SpA), or a functional fragment or variant thereof. The chromatography ligand presents an advantageous capability of withstanding harsh cleaning in place (CIP) conditions, and is capable of binding Fab fragments of antibodies. The ligand may be provided with a terminal coupling group, such as arginine or cysteine, to facilitate its coupling to an insoluble carrier such as beads or a membrane. The invention also relates to a process of using the ligand in isolation of antibodies, and to a purification protocol which may include washing steps and/or regeneration with alkali.

Chromatography ligand comprising domain c fromprotein a for antibody isolation

The present invention relates to a chromatography ligand, which comprises Domain C fromprotein A (SpA), or a functional fragment or variant thereof. The chromatography ligand presents an advantageous capability of withstanding harsh cleaning in place (CIF) conditions, and is capable of binding Fab fragments of antibodies. The ligand may be provided with a terminal coupling group, such as arginine or cysteine, to facilitate its coupling to an insoluble carrier such as beads or a membrane. The invention also relates process of using the ligand in isolation of antibodies, and to a purification protocol which may include washing steps and/or regeneration with alkali.

Chromatography ligand comprising domain C fromprotein A for antibody isolation

The present invention relates to a chromatography ligand, which comprises Domain C fromprotein A (SpA), or a functional fragment or variant thereof. The chromatography ligand presents an advantageous capability of withstanding harsh cleaning in place (CIP) conditions, and is capable of binding Fab fragments of antibodies. The ligand may be provided with a terminal coupling group, such as arginine or cysteine, to facilitate its coupling to an insoluble carrier such as beads or a membrane. The invention also relates process of using the ligand in isolation of antibodies, and to a purification protocol which may include washing steps and/or regeneration with alkali.

[object Object]

Growing community of inventors

Uppsala, Sweden

Sture Larsson